Puma Biotechnology to Join Russell 3000 Index
28 Mai 2024 - 3:00PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, is set to join the broad-market Russell 3000® Index at the
conclusion of Russell Investments’ annual reconstitution of its
comprehensive set of U.S. and global equity indexes on June 28 and
effective after U.S. markets open on July 1, according to a
preliminary list of additions posted on May 24.
“We are very pleased to be included in the widely referenced
Russell Indexes,” said Alan H. Auerbach, Chief Executive Officer
and President of Puma Biotechnology. “We believe that inclusion in
the Russell 3000 will benefit our stockholders by increasing
liquidity and providing exposure to a broader base of institutional
investors.”
Reconstitution of Russell’s U.S. Indexes captures the 4,000
largest U.S. stocks as of the end of April, ranking them by total
market capitalization. Membership in the Russell 3000, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell 2000® Index, as
well as the appropriate growth and value style indexes. The Russell
3000 also serves as the U.S. component to the Russell Global
Index.
Russell determines membership for its equity indexes primarily
by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Over $10 trillion in
assets are benchmarked against Russell’s U.S. Indexes. Russell
indexes are part of FTSE Russell, a leading global index
provider.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licensed the global
development and commercialization rights to PB272 (neratinib, oral)
in 2011. Neratinib, oral was approved by the U.S. Food and Drug
Administration in 2017 for the extended adjuvant treatment of adult
patients with early stage HER2-overexpressed/amplified breast
cancer, following adjuvant trastuzumab-based therapy, and is
marketed in the United States as NERLYNX® (neratinib) tablets. In
February 2020, NERLYNX was also approved by the FDA in combination
with capecitabine for the treatment of adult patients with advanced
or metastatic HER2-positive breast cancer who have received two or
more prior anti-HER2-based regimens in the metastatic setting.
NERLYNX was granted marketing authorization by the European
Commission in 2018 for the extended adjuvant treatment of adult
patients with early stage hormone receptor-positive
HER2-overexpressed/amplified breast cancer and who are less than
one year from completion of prior adjuvant trastuzumab-based
therapy. NERLYNX® is a registered trademark of Puma Biotechnology,
Inc.
In September 2022, Puma entered into an exclusive license
agreement for the development and commercialization of the
anti-cancer drug alisertib, a selective, small molecule, orally
administered inhibitor of aurora kinase A. Initially, Puma intends
to focus the development of alisertib on the treatment of small
cell lung cancer and breast cancer. In February 2024, Puma
initiated ALISCA-Lung 1, a Phase II clinical trial of alisertib
monotherapy for the treatment of patients with extensive-stage
small cell lung cancer.
Further information about Puma Biotechnology may be found at
www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that
involve risks and uncertainties that could cause Puma’s actual
results to differ materially from the anticipated results and
expectations expressed in these forward-looking statements. These
statements are based on current expectations, forecasts and
assumptions, and actual outcomes and results could differ
materially from these statements due to a number of factors, which
include, but are not limited to, the risk factors disclosed in the
periodic and current reports filed by Puma with the U.S. Securities
and Exchange Commission from time to time, including Puma’s Annual
Report on Form 10-K for the year ended December 31, 2023 and
subsequent reports. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Puma assumes no obligation to update these
forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240528591059/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.
+1 424 248 6500 info@pumabiotechnology.com ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024